| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES a) CARBOXIALKYL ETHER THAT PREFERENCES FORMULA I, WHERE n AND m ARE 2-9; R1, R2, R3, AND R4 ARE C1-C6 ALKYL, C2-C6 ALKYL, C2-C6 ALKYL; R1 AND R2 OR R3 AND R4 FORM A 3-6 MEMBER CARBOCYCLIC RING; Y1 AND Y2 ARE COOH, CHO, TETRAZOLE AND COOR5; R5 IS C1-C6 ALKYL, C2-C6 ALKENYL, C2-C6 ALKINYL, THE COMPOUND 6,6`-OXIBIS (2,2-DIMETHYLHEXANOIC) BEING MORE PREFERRED, WHICH REDUCES TRIGLYCERIDES AND HIGH DENSITY LIPOPROTEIN (HDL); b) A STATIN THAT INHIBITS THE REDUCTASE HMG-CoA 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE, WHICH PARTICIPATES IN THE BIOSYNTHESIS OF CHOLESTEROL, SUCH AS SIMVASTATIN, PRAVASTATIN, RIVASTATIN, DIALUVASTATIN, FLUVASTATIN, DIALUVASTATIN, FLUVASTATIN, DIALUVASTATINE , COMPACTIN, CERIVASTATIN, LOVASTATIN. THE COMPOSITION HAS A SYNERGIC EFFECT IN THE TREATMENT OF HYPERLIPIDEMIA. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF HYPERLIPIDEMIA, ANGINA PEAK, CARDIAC RISK, DIABETES, ATHEROSCLEROSIS, IT STILLS THE GROWTH OF ATHEROSCLEROTIC PLATES IN CORONARY ARTERIES, CAROTIDAL, ARTERIAL SYSTEM |